News Quantified

IMAB – i-mab - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

In This Article : [Yahoo! Finance]

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

I-Mab Leads Our Spotlight On 3 US Penny Stocks [Yahoo! Finance]

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.

2.9%

MISS

-14.6%

BEAT

Form 6-K I-Mab For: Jan 06

Form 6-K I-Mab For: Dec 03

Form 6-K I-Mab For: Nov 14

Form 6-K I-Mab For: Nov 06

Form 6-K I-Mab For: Nov 05

Top News Gainers

2/25 I-Mab Announces Upcoming Participation at March Conferences 15.1%

4/29 Form 20-F I-Mab For: Dec 31 14.5%

3/27 Form 6-K I-Mab For: Mar 27 8.2%

4/2 I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China 7.5%

3/13 I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19) 7.2%

3/30 Form 6-K I-Mab For: Mar 30 4.0%

4/17 Form 6-K I-Mab For: Apr 17 3.9%

4/15 I-Mab (IMAB) Investor Presentation - Slideshow [Seeking Alpha] 3.3%

2/10 I-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public Offering 1.6%

4/24 I-Mab Announces Upcoming Participation at May Conferences 0.9%

Top News Decliners

3/13 Form 6-K I-Mab For: Mar 13 -15.9%

1/17 I-MAB Announces Pricing of U.S. Initial Public Offering -15.3%

3/30 I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea -7.4%

4/6 Form 6-K I-Mab For: Apr 06 -5.7%

4/6 I-Mab Announces Upcoming Participation at April Conferences -4.9%

3/11 I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020 -3.9%

2/14 Form SEC STAFF LETTER I-Mab -3.0%

2/12 Phoenix Tree Holdings Limited (NASDAQ: IMAB) is now covered by analysts at China Renaissance Securities Ltd.. They set a "buy" rating on the stock. -1.6%

3/23 Form 6-K I-Mab For: Mar 23 -1.3%

4/28 Form 6-K I-Mab For: Apr 28 -0.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day